FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
04 | Association of a novel TERT polymorphism with poorer survival in male patients with melanoma Fortunato Cassalia1, Maria Santa Rocca2, Andrea Di Nisio3, Paolo del Fiore*4, Clara Benna5|7, Ilaria Cosci6, Simone Mocellin4|5, Alberto Ferlin*2|6 | 1Department of Dermatology, University of Padua, Padua; 2Unit of Andrology and Reproductive Medicine, University Hospital of Padua, Padua; 3Department of Wellbeing, Nutrition and Sport, Pegaso Telematic University, Naples; 4Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 5Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua; 6Department of Medicine, University of Padua, Padua; 7Unit of Biostatistics, Epidemiology and Public Health, Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.
346 -
The top 100 most cited articles in acne vulgaris: a bibliometric analysis
3134PDF: 582SUPPLEMENTARY MATERIAL: 172HTML: 15 -
Primary malignant melanoma with pseudovascular morphology: a diagnostic pitfall
151PDF: 75SUPPLEMENTARY MATERIAL: 52 -
13 | Spatial contexture of tertiary lymphoid structures as a predictor of recurrence in early-stage melanoma Chiara Bungaro1, Sabino Strippoli1, Daniele Carenza1, Ivana De Risi1, Rossella Villani1, Teresa Squicciarini1, Anna Albano1, Ileana De Roma1, Fabio Mele 2, Margherita Sonnessa2, Concetta Saponaro2, Francesco Alfredo Zito2, Arianna Bozzi3, Benedetta Apollonio1, Raffaella Massafra3, Michele Guida1 | 1Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II"; 2Pathology Unit, IRCCS Istituto Tumori "Giovanni Paolo II"; 3Biostatistics and Bioinformatics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
336 -
25 | A phase II, open-label study to improve compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas – the SONIBEC trial Monica Variolo1|2, Carlo Resteghini1|2, Sara Farinatti1|2, Andrea Alberti3, Valeria Tovazzi3, Paola Queirolo4, Maristella Saponara4, Giuseppe Argenziano5, Riccardo Marconcini6, Ketty Peris7, Paola Savoia8, Maria Chiara Tronconi1, Iris Zalaudek9, Paolo Ascierto10, Francesco Spagnolo11, Luigi Lorini1, Cristina Gurizzan1, Paolo Bossi1|2 | 1Medical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, Rozzano MI; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; 3Medical Oncology Unit, ASST Spedali Civili, Brescia; 4Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan; 5Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; 6Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; 7Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; 8Department of Health Sciences, University of Eastern Piedmont, Novara; 9Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste; 10Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; 11Department of Medical Oncology, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
320 -
Blue diode laser as supportive therapy for the management of vulvar lichen sclerosus
2380PDF: 791SUPPLEMENTARY MATERIAL: 259HTML: 142 -
Cutaneous lesions as presentation form of mantle cell lymphoma
1995PDF: 624HTML: 6072 -
Telangiectasia Macularis Eruptiva Perstans: more than skin deep
11685PDF: 2218HTML: 2302 -

